NASDAQ: MNOV - MediciNova, Inc.

Rentabilité sur six mois: -21.89%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions MediciNova, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise MediciNova, Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.

plus de détails
The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2005-02-08
ISIN US58468P2065
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.medicinova.com
Цена ао 1.47
Changement de prix par jour: +3.21% (1.4)
Changement de prix par semaine: +16.53% (1.24)
Changement de prix par mois: -6.77% (1.55)
Changement de prix sur 3 mois: -24.35% (1.91)
Changement de prix sur six mois: -21.89% (1.85)
Changement de prix par an: -6.17% (1.54)
Evolution du prix sur 3 ans: -51.83% (3)
Evolution du prix sur 5 ans: -55.95% (3.28)
Evolution des prix depuis le début de l'année: -39.29% (2.38)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 71.61 1
P/BV 1.15 9
P/E 0 0
EV/EBITDA -2.11 0
Total: 4.63

Efficacité

Nom Signification Grade
ROA, % -12.93 0
ROE, % -13.74 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0219 10
Total: 8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 24.6 4
Rentabilité Ebitda, % -29.43 0
Rentabilité EPS, % -41.73 0
Total: 0.8
Plus de détails

Établissements Volume Partager, %
Essex Woodlands Management Inc. 1105941 2.25
Blackrock Inc. 699642 1.43
Vanguard Group Inc 623333 1.27
Citigroup Inc. 447957 0.91
Geode Capital Management, LLC 435733 0.89
Renaissance Technologies, LLC 174100 0.35
Bank of America Corporation 167959 0.34
State Street Corporation 157198 0.32
Northern Trust Corporation 153556 0.31
Dimensional Fund Advisors LP 152530 0.31



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Yuichi Iwaki M.D., Ph.D. Co-Founder, President, CEO & Executive Director 907.26k 1950 (75 années)
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. Chief Medical Officer & Director 649.05k 1966 (59 années)
Mr. Jason J. Kruger CPA CFO & Principal Financial Officer N/A 1978 (47 années)
Dr. David H. Crean M.B.A., Ph.D. Chief Business Officer N/A 1965 (60 années)
Mr. John O'Neil CPA Controller

Adresse: United States, La Jolla. CA, 4275 Executive Square - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.medicinova.com